Roxanne C. Jewell

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 796 citations

Medicine, Pharmacology, Pharmacotherapy +11

Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918

C.M.F. Kruijtzer, Jos H. Beijnen, Hilde Rosing et al. · Journal of Clinical Oncology · 2002 · 462 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

I. E. L. M. Kuppens, Els O. Witteveen, Roxanne C. Jewell et al. · Clinical Cancer Research · 2007 · 176 citations

Medicine, Oncology, Pharmacology +16

Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer

Michael J. Robertson, James W. Mier, Theodore F. Logan et al. · Clinical Cancer Research · 2006 · 170 citations

Medicine, Oncology, Pharmacology +10

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

Mirte M. Malingré, Jos H. Beijnen, Hilde Rosing et al. · British Journal of Cancer · 2001 · 151 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17